Early Access Programs News Today

Clinigen launches ‘What is Possible?’ campaign to accelerate access to medicines on  Rare Disease Day  With over 7,000 rare diseases that impact over 300 million people globally, just 5% of rare diseases have a licensed treatment*  LONDON, UK, 29 February 2024 – Clinig...

Investegate announcements from Placing and Subscription

The following is a round-up of earnings of London-listed companies, issued on Wednesday and not separately reported by Alliance News: ---------- ASA International Group PLC - Weybridge, Surrey-based...

Quoin announced dosing of first patient in double blinded clinical study to evaluate QRX003 for Netherton SyndromeQuoin announced initiation of a second...

COVA study met primary end point with 44% significant reduction in the risk of respiratory failure or early deathFiling for Early Access Programs to Sarconeos (BIO101) is being initated while preparing

Biophytis / Key word(s): Miscellaneous Biophytis announces positive final results of the phase 2-3 COVA study with Sarconeos (BIO1...

Biophytis / Key word(s): Miscellaneous Biophytis announces positive final results of the phase 2-3 COVA study with Sarconeos (BIO101) in severe COVID-19 02-Feb-2023 / 08:00 CET/CEST Biophytis announces positive final results of the phase 2-3 COVA study with Sarconeos (BIO101) in severe COVID-19   C...

Prescription product net revenue of approximately $3.1 million in Q3 2022 increased 8.2% over Q2 2022 and increased approximately 412% over prescription product net revenue in Q3 2021Core initiatives:OnTarget

Special Note Regarding Forward-Looking Statements Certain statements in this Report contain forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of... | November 14, 2022

Company completed a public offering for aggregate gross proceeds of $16.8 millionMajority of clinical sites now open in clinical study to evaluate QRX003...